| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Vigil Neuroscience, Inc. | Director | Common Stock | 1.56M | $5.84M | $3.75 | May 17, 2022 | By Hatteras Venture Partners VI, L.P. |
| Clearside Biomedical, Inc. | Director | Common Stock | 176K | $162K | $0.92 | Feb 24, 2025 | Direct |
| Vigil Neuroscience, Inc. | Director | Common Stock | 3K | $11.3K | $3.75 | May 16, 2022 | Direct |
| PhaseBio Pharmaceuticals Inc | Director | Common Stock | 3.55M | May 19, 2023 | Indirect | ||
| Clearside Biomedical, Inc. | Director | Stock Option (right to buy) | 45K | Jun 20, 2024 | Direct | ||
| PhaseBio Pharmaceuticals Inc | Director | Common Stock | 36.7K | May 19, 2023 | Direct | ||
| PhaseBio Pharmaceuticals Inc | Director | Non-employee Director Stock Option (right to buy) | 17.5K | May 19, 2022 | Direct | ||
| PhaseBio Pharmaceuticals Inc | Director | Restricted Stock Units | 0 | May 19, 2023 | Direct | ||
| Vigil Neuroscience, Inc. | Director | Series A Preferred Stock | 0 | Jan 11, 2022 | By Hatteras Venture Partners VI, L.P. | ||
| Vigil Neuroscience, Inc. | Director | Series B Preferred Stock | 0 | Jan 11, 2022 | By Hatteras Venture Partners VI, L.P. |